ARGX to acquire FBRX for $77 per share in cash.
ARGX to acquire FBRX for $77 per share in cash.
Story updates
10:23:10 AM UTC
SquawkNews
FBRX +39% premarket; Argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline ARGX Argenx, a global immunology innovation company, and Forte Biosciences, Inc. today announced that the companies have entered into a definitive agreement under which Argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2B.
FBRX +39% premarket; Argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline ARGX Argenx, a global immunology innovation company, and Forte Biosciences, Inc. today announced that the companies have entered into a definitive agreement under which Argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2B.